NASDAQ: ALEC | Healthcare / Biotechnology / USA |
6.09 | -0.1700 | -2.72% | Vol 524.37K | 1Y Perf -34.45% |
Oct 4th, 2023 16:00 DELAYED |
BID | 6.05 | ASK | 6.13 | ||
Open | 6.21 | Previous Close | 6.26 | ||
Pre-Market | - | After-Market | 6.05 | ||
- - | -0.04 -0.66% |
Target Price | 17.50 | Analyst Rating | Moderate Buy 1.83 | |
Potential % | 187.36 | Finscreener Ranking | ★★★+ 51.00 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★+ 43.67 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★+ 53.53 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 22.75 | Earnings Rating | Strong Buy | |
Market Cap | 510.53M | Earnings Date | 14th Nov 2023 | |
Alpha | -0.01 | Standard Deviation | 0.18 | |
Beta | 0.66 |
Today's Price Range 5.946.21 | 52W Range 4.989.86 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -5.15% | ||
1 Month | 12.39% | ||
3 Months | 3.81% | ||
6 Months | 3.99% | ||
1 Year | -34.45% | ||
3 Years | -38.14% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -73.64 | |||
ROE last 12 Months | -50.77 | |||
ROA (5Y Avg) | -9.52 | |||
ROA last 12 Months | -17.49 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -40.02 | |||
Return on invested Capital Q | -14.61 | |||
Return on invested Capital Y | -15.18 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 18.50 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-5.00 | ||||
2.70 | ||||
5.63 | ||||
1.20 | ||||
27.00 | ||||
-0.25 | ||||
2.70 | ||||
3.06 | ||||
-31 573 300.00 | ||||
Forward PE | -2.72 | |||
PEG | -0.10 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
4.80 | ||||
4.80 | ||||
0.13 | ||||
0.18 | ||||
- | ||||
Leverage Ratio | 3.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-103.70 | ||||
-97.30 | ||||
-570.80 | ||||
-67.87 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
119.18M | ||||
1.44 | ||||
93.64 | ||||
137.20 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.81 | 0.02 | 102.47 |
Q01 2023 | -0.75 | -0.55 | 26.67 |
Q04 2022 | -0.54 | -0.63 | -16.67 |
Q03 2022 | -0.43 | -0.56 | -30.23 |
Q02 2022 | -0.39 | 0.12 | 130.77 |
Q01 2022 | 0.37 | -0.54 | -245.95 |
Q04 2021 | -0.13 | -0.68 | -423.08 |
Q03 2021 | 2.98 | 1.49 | -50.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.62 | 19.48 | Positive |
12/2023 QR | -0.69 | 20.69 | Positive |
12/2023 FY | -1.86 | 39.22 | Positive |
12/2024 FY | -2.38 | 17.65 | Positive |
Next Report Date | 14th Nov 2023 |
Estimated EPS Next Report | -0.62 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 524.37K |
Shares Outstanding | 83.83K |
Shares Float | 60.19M |
Trades Count | 6.57K |
Dollar Volume | 3.18M |
Avg. Volume | 689.72K |
Avg. Weekly Volume | 532.53K |
Avg. Monthly Volume | 910.30K |
Avg. Quarterly Volume | 626.32K |
Alector Inc. (NASDAQ: ALEC) stock closed at 6.26 per share at the end of the most recent trading day (a 1.13% change compared to the prior day closing price) with a volume of 468.73K shares and market capitalization of 510.52M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 171 people. Alector Inc. CEO is Arnon Rosenthal.
The one-year performance of Alector Inc. stock is -34.45%, while year-to-date (YTD) performance is -32.18%. ALEC stock has a five-year performance of %. Its 52-week range is between 4.98 and 9.86, which gives ALEC stock a 52-week price range ratio of 22.75%
Alector Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 2.70, a price-to-sale (PS) ratio of 5.63, a price to cashflow ratio of 1.20, a PEG ratio of -0.10, a ROA of -17.49%, a ROC of -40.02% and a ROE of -50.77%. The company’s profit margin is -67.87%, its EBITDA margin is -97.30%, and its revenue ttm is $119.18 Million , which makes it $1.44 revenue per share.
Of the last four earnings reports from Alector Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.62 for the next earnings report. Alector Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Alector Inc. is Moderate Buy (1.83), with a target price of $17.5, which is +187.36% compared to the current price. The earnings rating for Alector Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alector Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alector Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.58, ATR14 : 0.48, CCI20 : -5.59, Chaikin Money Flow : 0.41, MACD : 0.04, Money Flow Index : 47.09, ROC : -4.57, RSI : 48.69, STOCH (14,3) : 39.76, STOCH RSI : 0.09, UO : 63.21, Williams %R : -60.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alector Inc. in the last 12-months were: Arnon Rosenthal (Sold 15 186 shares of value $94 428 ), Gary Romano (Sold 2 771 shares of value $14 381 ), Grasso Marc (Sold 3 455 shares of value $23 768 ), Kenkare-Mitra Sara (Sold 20 430 shares of value $144 717 ), Mcguire Terrance (Sold 500 000 shares of value $3 000 000 ), Rosenthal Arnon (Sold 31 937 shares of value $208 688 ), Venture Management Co. Vi, L.L.C. Polaris (Sold 500 000 shares of value $3 000 000 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain.
CEO: Arnon Rosenthal
Telephone: +1 415 231-5660
Address: 131 Oyster Point Boulevard, South San Francisco 94080, CA, US
Number of employees: 171
Mon, 25 Sep 2023 08:50 GMT Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Alector (ALEC) and Vaccitech Plc (VACC)
- TipRanks. All rights reserved.Thu, 10 Aug 2023 17:55 GMT Alector (ALEC) Receives a Buy from Mizuho Securities
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.